Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?
A Discussion Of Current Deal Trends
Executive Summary
Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.
You may also be interested in...
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.